These initial results highlight that Blisterscan is much more reliable, accurate and capable of detecting 15 micron leaks than blue dye.
(Vocus) November 1, 2010
Specialist machinery manufacturer, Sepha Ltd, is urging pharma packaging and pharmaceutical manufacturers to start think smarter about packaging leak testing procedures in advance of a major, academic White Paper to be published later this year. The in-depth study into the accuracy of the technology-based leak detection device, Blisterscan, verses traditional blue dye test methods is being carried out by Professor Dorian Dixon of the University of Ulster's School of Engineering.
Initial results of the study were presented to Sepha's worldwide agent & distributor network at a major global conference held in Belfast recently. Dr Dixon said: " These initial results highlight that Blisterscan is much more reliable, accurate and capable of detecting 15 micron leaks than blue dye." Further tests on 10, 15, and 20 micron holes will be carried out as Dr Dixon moves towards the completion of his White Paper at the end of 2010. Improved accuracy and reliability of blister pack testing, combined with non-destructive cost-savings present a strong argument for Blisterscan to become the most appropriate leak detection device in modern pharma production facilities.
Agents who travelled from as far as India, China and Brazil to attend the three day conference were also introduced to three new pharmaceutical packaging machine prototypes developed in response to the economic challenges facing the global pharmaceutical industry. The new machines will offer effective yet lower cost options for detecting leaks in pharmaceutical packaging such as blister packs.
Sepha is a specialist manufacturer of non-destructive inspection equipment for inspecting the seal integrity of pharmaceutical and medical device blister packs. Sepha also designs and manufactures a range of deblistering equipment for product recovery from pharmaceutical blisters and lab-scale blister packing machines for clinical trial use.